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During cell division, cells form the microtubule-
based mitotic spindle, a highly specialized and
dynamic structure that mediates proper chromo-
some transmission to daughter cells. Cancer cells
can show perturbed mitotic spindles and an ap-
proach in cancer treatment has been to trigger cell
killing by targeting microtubule dynamics or spindle
assembly. To identify and characterize proteins
necessary for spindle assembly, and potential anti-
mitotic targets, we performed a proteomic and
genetic analysis of 592mitoticmicrotubule copurify-
ing proteins (MMCPs). Screening for regulators that
affect both mitosis and apoptosis, we report the
identification and characterization of STARD9, a
kinesin-3 family member, which localizes to centro-
somes and stabilizes the pericentriolar material
(PCM). STARD9-depleted cells have fragmented
PCM, form multipolar spindles, activate the spindle
assembly checkpoint (SAC), arrest in mitosis, and
undergo apoptosis. Interestingly, STARD9-depletion
synergizes with the chemotherapeutic agent taxol to
increase mitotic death, demonstrating that STARD9
is a mitotic kinesin and a potential antimitotic target.INTRODUCTION
Mitotic spindle assembly is a highly complex and orchestrated
event that organizes cell division. Mitosis relies on a multitude
of protein complexes, protein-protein interactions, and regula-
tory mechanisms (Walczak and Heald, 2008). To date, many
proteins that associate with microtubules and function in mitoticspindle assembly have been identified and characterized
(Loughlin et al., 2008; Manning and Compton, 2008a, 2008b;
Walczak and Heald, 2008). Nonmotor proteins, for example,
function in microtubule nucleation, crosslinking, and stability,
and they can influence the activities of motor proteins (Manning
and Compton, 2008b). Motor proteins, in addition to their trans-
port roles, influence microtubule dynamics, kinetochore micro-
tubule attachment, and centrosome separation (Walczak and
Heald, 2008).
A strategy in the treatment of cancer has been to inhibit cell
division with antimitotic drugs, a set of natural and synthetic
small molecules that characteristically arrest cells in mitosis,
and induce programmed cell death (Gascoigne and Taylor,
2008; Shi et al., 2008). The spindle is the major target of antimi-
totics and three major microtubule spindle targets and associ-
ated inhibitors have been explored in the clinic: microtubule
inhibitors including taxanes and epothilones; inhibitors of the
Polo-like kinase Plk1, a regulator of spindle assembly, including
BI 2536; and inhibitors of the mitotic kinesin-5, including monas-
trol and ispinesib (Kapoor et al., 2000; Lansing et al., 2007).
Recent clinical trials have questioned the long-term efficacy of
current antimitotic drugs. Although taxol remains the most
widely-used and efficacious chemotherapeutic agent, it shows
dose-limiting toxicities, including neutropenia and severe
neuropathies, driving a need to identify alternative antimitotic
drug targets that can be targeted and combined with lower
doses of taxol to reduce the toxicity associated with high-dose
taxol.
To identify proteins involved in mitotic spindle assembly, the
linkage to cell death, and thus uncover potential targets for
cancer therapeutics, we performed a proteomic analysis to iden-
tify mitotic microtubule copurifying proteins (MMCPs) and
genetic RNAi screening to test the contribution of these proteins
to mitotic progression and induction of apoptosis. We report the
results of these screens, which we exemplify by the identification
and characterization of STARD9, a mitotic kinesin. STARD9 isCell 147, 1309–1323, December 9, 2011 ª2011 Elsevier Inc. 1309
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Figure 1. Proteomic and In Silico Analysis of MMCPs
(A) Workflow for purification and identification of MMCPs.
(B) In vitro mitotic aster microtubule polymerization reactions ± taxol, visualized with anti a–tubulin antibodies.
(C) Immunoblot analysis of supernatant (S) and pellet (P) fractions from microtubule polymerization reactions. Blots were probed with anti Kinesin-5, CycD, and
a–tubulin antibodies.
(D) Purifiedmicrotubule pellets and associated proteins were analyzed by SDS-PAGE and stainedwith Coomassie blue. E, input extract. Microtubule pellets were
digested in solution and proteins identified by LC-MS/MS.
(E) In silico analysis of 592 genes and encoded proteins, for details see text and Supplemental Information.
(F) Generation of a siRNA library targeting 592 genes corresponding to the MMCP set. (A–F) See also Extended Experimental Procedures and Tables S1 and S2.necessary for PCM cohesion during the establishment of spindle
bipolarity. The absence of STARD9 causes the pericentriolar
material to fragment and dissociate from the centrioles, along
with a failure to congress chromosomes, multipolar spindle
formation, mitotic arrest, and apoptotic cell death. Most impor-
tantly, depletion of STARD9 synergizes with taxol treatment,
making STARD9 a candidate target to extend current cancer
therapeutics.
RESULTS
Identification of Mitotic Microtubule Copurifying
Proteins
To identify MMCPs that contribute to mitotic spindle formation,
we performed a proteomic analysis of microtubule aster copur-
ifying proteins (Figures 1A–1D). Mitotic HeLa cell extracts were
induced to undergo in vitro microtubule polymerization in the
presence or absence of the microtubule-stabilizing drug, taxol
(see Mack and Compton, 2001) (Figure 1B). Polymerized micro-
tubules and associated proteins were purified by sedimentation
through a sucrose cushion. The selectivity of the purification was
assessed by immunoblotting protein samples from the superna-
tant (S) and the pelleted microtubule aster (P) fractions for1310 Cell 147, 1309–1323, December 9, 2011 ª2011 Elsevier Inc.Kinesin-5 and cyclin D (Figure 1C). Kinesin-5 associated with
the taxol stabilized microtubule pellet, whereas cyclin D
remained in the supernatant (Figure 1C). Neither protein pelleted
in the absence of taxol, demonstrating minimal nonspecific pel-
leting (Figure 1C). Purified microtubule asters were trypsinized in
solution and 592 MMCPs were identified by mass spectrometry
(LC-MS/MS) (Figure 1D, Table S1, and Supplemental Informa-
tion available online).
To understand the potential roles of these proteins in cell divi-
sion, the 592 MMCPs were systematically queried in PubMed
and one of eight functional annotations was assigned to each
protein based on existing literature (Figure 1E and Table S1).
25% of the proteins had a previously validated role in microtu-
bule dynamics and stability, including TPX2, NuMA, and Astrin.
Another 14% were involved in spindle-associated activities,
including spindle checkpoints, kinetochore-microtubule attach-
ment, centrosome homeostasis, regulation of mitosis, or were
microtubule-based molecular motors including kinesins. Inter-
estingly, over half of the proteins were either uncharacterized
or had not been linked to mitotic spindle assembly (Figure 1E
and Table S1).
The domain compositions of the 592 MMCPs were
analyzed by querying the Unison (http://unison-db.org) (Hart
and Mukhyala, 2009) database, which calculates the pres-
ence of domains from the Pfam (Finn et al., 2008) and Prosite
(Hulo et al., 2006) databases, as well as from signal
sequence and transmembrane prediction algorithms (see
Extended Experimental Procedures). Proteins and domains
were hierarchically clustered (Eisen et al., 1998) using the
Pearson correlations of the numbers of each domain appear-
ing in each protein (Tables S1 and S2). A notable cluster of
21 MMCPs contained kinesin motor domains, including an
uncharacterized protein STARD9, a family of ATPases whose
members are important for spindle bipolarity, spindle pole
focusing, kinetochore function, and regulation of microtubule
dynamics.
Functional Characterization of MMCPs
To assess the contribution of MMCPs to mitotic progression,
we developed a siRNA library targeting the knockdown of all
MMCP-encoding genes (Figure 1F). The library was used to
perform four functional screens: mitotic arrest; mitotic spindle
assembly checkpoint (SAC) bypass; induction of apoptosis;
and synergy with taxol to induce apoptosis (Figures 2A–2H,
Table S3, Supplemental Information). Due to space constraints
we focus our discussion on two screens. First, we sought to
identify gene depletions leading to mitotic arrest. HeLa cells
were reverse transfected with siRNAs for 48 hr prior to fixation
and staining with Hoechst (DNA dye) and anti p-H3 antibodies,
which recognize phosphorylated histone H3 (a marker of mitotic
cells). Data was collected on 1,000 Hoechst positive cells per
well using an image-based, high-content screening micro-
scope. The mitotic index (MI) per well was derived from the
number of mitotic nuclei (p-H3 positive) divided by the total
nuclei (Hoechst positive) (Figure 2B). The results were graphed
as scatter plots, with normalized MI on the y axis (in log scale)
and individual oligonucleotides spread across the x axis. 194
siRNAs, corresponding to 138 genes showed an increased MI
greater than two standard deviations from the mean, and within
this set 32 genes had two or more oligonucleotides score as hits
(Figure 2C and Table S3). The majority of these gene products
had a validated role in spindle assembly like TOGp, TPX2,
TACC3, and Kinein-5. Additionally, this set also included
multiple proteins with potential roles in spindle assembly, like
STARD9.
Next, we screened for gene depletions leading to apoptosis
(Figure 2E–2H). Apoptosis relies on caspase 3/7 activity (Chowd-
hury et al., 2008). Therefore, we used a luciferase-based assay
(caspase substrate linked to luciferin, which when cleaved is
converted to light by luciferase and can be measured by a lumin-
ometer) to measure total caspase 3/7 activities (Caspase-Glo
assay) per well. Additionally, the CellTiter-Glo assay, which
measures total ATP levels (indicative of metabolically active
cells) was used to measure the number of viable cells per well.
HeLa cells were transfected with siRNA and the apoptotic index
(AI, caspase activity per cell/ATP levels as described in (Peterson
et al., 2010) was measured 72 hr posttransfection (Figure 2F).
Depletion of 45 genes (with R 2 oligonucleotides scored as
hits) showed an increased AI one standard deviation above the
mean (Figure 2G). Among this set were Plk1, NuMA, AF15Q14,
and STARD9.Identification of STARD9
When inhibited, antimitotic targets arrest cells in mitosis and
induce apoptosis (Gascoigne and Taylor, 2008; Shi et al.,
2008). To assess the potential of MMCPs as antimitotic drug
targets, we performed a correlation analysis of the normalized
MI and normalized AI for each oligonucleotide from our screens
(Figure 2I). This separated data into 4 quadrants, including
a quadrant with 39 genes whose depletion caused an increase
in both MI and AI (Figures 2I and 2J). This quadrant included
Plk1 and Kinesin-5 whose depletion have been previously
demonstrated to both induce mitotic arrest and activate the
apoptotic response (Petronczki et al., 2008; Shi et al., 2008) (Fig-
ure 2J). Within this set we identified STARD9 (steroidgenic acute
regulatory protein-related lipid transfer (START) domain contain-
ing 9), a previously uncharacterized kinesin-like protein (Halama
et al., 2006) (Figure 2J). STARD9 was selected for further anal-
ysis, based on its copurification with mitotic microtubule asters,
requirement for mitotic progression, role in suppressing
apoptosis, and novelty as a mitotic kinesin.
STARD9 Is a Kinesin-3 Family Member
Database searches predicted three STARD9 isoforms; the
longest encoding a 4,614 amino acid protein with an apparent
molecular mass of 506.7 kDa (Figures S1A, S1B, and 3A).
STARD9 is a member of the Kinesin-3 family, and shares 52%
and 48% sequence identity within the motor domain (amino
acids 1-374) with its closest human paralogues KIF16B and
KIF1A respectively (Lawrence et al., 2004; Wickstead and Gull,
2006) (Figure 3B). The Kinesin-3 family (composed of the KIF1,
KIF13, KIF14, KIF16, and KIF28 subfamilies) is implicated in
transporting vesicles and organelles (Hoepfner et al., 2005;
Miki et al., 2005; Nangaku et al., 1994). The STARD9 motor
and FHA domains are conserved among all family members
(Vale, 2003). STARD9 also has a C-terminal START domain pre-
dicted to bind phospholipids and/or sterols, analogous to the
KIF1A/KIF1B PH domain and the KIF16B PX domain that
bind phospholipids (Alpy and Tomasetto, 2005). Interestingly,
STARD9 has a unique 26 amino acid residue insertion in loop
12, a microtubule interaction region of kinesins (Figure 3B).
STARD9 is ubiquitously expressed at low levels in all tissues
analyzed, including skin, brain, and heart (Figure S1C). Addition-
ally, STARD9 orthologs are only found in vertebrates (Figure S2).
STARD9 Localizes to Daughter Centrioles during
Mitosis
To assess the role of STARD9 in mitosis, we analyzed its sub-
cellular localization through the cell cycle. HeLa cells were fixed
and costained for DNA, STARD9, and a–tubulin. STARD9 was
distributed throughout the nucleus and cytoplasm in interphase,
localized to the centrosomes from prophase to late anaphase,
and disappeared at cytokinesis (Figure 3C, see arrows). To
define the localization of STARD9, we performed colocalization
studies with centrosome and spindle pole markers (Figure 3D).
Centrin staining detects two centrioles per centrosome and
STARD9 consistently colocalized to one of the two centrioles
(Figure 3D, panel 1 zoom). STARD9 also colocalized with peri-
centrin and g–tubulin and localized to the outer periphery of
the spindle pole as defined by NUMA, TPX2, and Kinesin-5Cell 147, 1309–1323, December 9, 2011 ª2011 Elsevier Inc. 1311
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Figure 2. Functional Characterization of MMCPs
(A) Schematic of mitotic arrest and mitotic checkpoint bypass RNAi screens.
(B) The mitotic index (MI = # cells phosphohistone H3 positive/total # Hoechst stained nuclei) was quantified per well.
(C and D) RNAi screen summary scatter plots for individual oligonucleotides ± taxol. Individual oligonucleotides are spread across the x axis and MI along the
y axis. Solid line represents mean and dashed and dotted lines indicate one and two standard deviations from the mean of control oligonucleotides, respectively.
(E) Schematic of RNAi screens for detection of increased apoptosis and synergy with taxol to induce apoptosis.
(F) The apoptotic index (AI) was quantified as the total caspase 3/7 activities (Caspase-Glo) divided by the total ATP levels (CellTiter-Glo) per well.
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staining (Figure 3D, panels 2–6 zoom). Interestingly, STARD9
colocalized with centrobin, a notable daughter centriole-associ-
ated protein (Figure 3E, see zoom) (Zou et al., 2005). Thus, the
localization of STARD9 to daughter centrioles is cell-cycle
specific. Additionally, in cells containing multiple centrosomes,
STARD9 only localized to the daughter centrioles of two centro-
somes (Figure S3A), suggesting that it is under a restrictive
control that blocks its appearance at supernumerary centrioles.
The STARD9 Motor Domain Contains Microtubule
Binding and ATPase Activities
STARD9 is a kinesin-like protein with no previous molecular
dissection, thus we analyzed whether GST-tagged STARD9
motor domain (MD) fusion proteins, wild-type (WT) and mutants
could bind microtubules and undergo an ATPase cycle, two
defining properties of kinesins. Mutant T110N is a threonine to
asparagine substitution at position 110 within the P loop of the
ATP binding site, predicted to show rigor binding tomicrotubules
with no ATP hydrolysis ormovement (Blangy et al., 1998). Mutant
R223A is an arginine to alanine substitution within the Switch I
region, predicted to reduce its affinity for microtubules (Yun
et al., 2001). For microtubule binding assays (as described in
Goode and Feinstein, 1994), MD-WT and MD mutants were
incubated with or without polymerized microtubules and their
ability to bind microtubules was determined by pelleting micro-
tubules at 100,000 3 g and analyzing samples from the pellet
and supernatant by SDS-PAGE and Coomassie blue staining
(Figure 4A). Similar to microtubule associated protein 2 (Map2,
positive control) MD-WT and MD-T110N pelleted with microtu-
bules. However, MD-R223A showed a significantly reduced
ability to pellet with microtubules (Figure 4A). Next, the ATP-
hydrolyzing activity of STARD9 was analyzed by performing
ATPase assays (enzyme linked inorganic phosphate assay,
Cytoskeleton Inc.) in the presence or absence of microtubules
(Figure 4B). In this assay ATP hydrolysis releases inorganic phos-
phate (Pi), which is converted into an absorbance shift from
330 to 360 nm that can be measured by a spectrophotometer
(Webb, 1992). Similar to kinesin heavy chain, MD-WT displayed
microtubule-stimulated ATPase activity. However, MD-T110N
and Skp1 (negative control) showed minimal ATPase activity
(Figure 4B). Therefore, the motor domain of STARD9 possesses
microtubule binding and ATP hydrolyzing activities comparable
to that of other kinesins.
Kinesins rely on their microtubule binding and ATP hydrolyzing
activities to localize to specific subcellular structures. Thus,
we analyzed whether STARD9s localization to centrioles was
dependent on these activities. EGFP-tagged MD-WT, MD-
T110N, and MD-R223A were expressed in HeLa cells and their
localization was monitored by immunofluorescence. EFGP-
MD-WT localized to the daughter centriole, consistent with
endogenous STARD9 localization, along with the mother cen-
triole and the surrounding PCM, indicating that this truncated(G and H) Apoptosis screens summary scatter plots for individual oligonucleotide
Graphs are as in (D).
(I) Correlation analysis of individual oligonucleotides in - taxol screens, based on n
control oligonucleotides) (x axis). Rectangle represents quadrant containing gen
(J) List of top hits with increased MI and AI. (A–J) See also Extended Experimentfragment lacked determinants that selectively target it to the
daughter centriole (Figure 4C). Consistently, GST-MD-WT, but
not a control GST-Skp1, was able to bind a–tubulin and the cen-
trosomal proteins g–tubulin, pericentrin, and MCAK in capture
assays with purified centrosomes (Figure 4D). However, eGFP-
MD-T110N and -MD-R223A were unable to localize to centro-
somes (Figure 4C). These data indicate that the STARD9 micro-
tubule binding and ATP hydrolyzing activities are required for its
localization to centrosomes.
Depletion of STARD9 Induces PCM Fragmentation
in Varied Cancer Cell Lines
To understand the role of STARD9 in mitosis, we analyzed the
cellular consequences of depleting STARD9. First, we identified
two siRNA oligonucleotides, which reduced STARD9 mRNA
levels to less than 10% (oligonucleotides 1 (herein referred to
as siSTARD9) and 4) (Table S4). HeLa cells were transfected
with siSTARD9 for 48 hr and the effect on mitosis was analyzed
by costaining for DNA, centromeres, and a-tubulin (Figure 5A).
STARD9-depleted cells failed to congress mitotic chromo-
somes, which remained scattered along a defective multipolar
spindle (Figure 5A). Consistently, no STARD9 daughter centriole
staining was observed in siSTARD9 cells, showing the specificity
of these antibodies for STARD9 (Figure S3B). Similar defects
were observed with STARD9 siRNA oligonucleotide 4 (Figures
S3C and S3D).
Multiple pathways exist for generating multipolar spindles,
including centrosome amplification, centriole fragmentation,
centriole splitting, and pericentriolar material (PCM) fragmenta-
tion (Fukasawa, 2007; Oshimori et al., 2006). To define themech-
anism(s) by which siSTARD9 cells generate multipolar spindles,
we visualized the status of the centrosomes, centrioles (centrin)
and PCM (pericentrin). Similar to siControl cells, mitotic
siSTARD9 cells had two centrosomes with no centriole splitting
or fragmentation (Figure 5B). In interphase, > 90% of siControl
and siSTARD9 cells had one or two pericentrin or g-tubulin
foci, indicating that STARD9 depletion did not trigger cen-
trosome over-duplication (Figures 5C and 5D). In mitosis, 82%
of siSTARD9 cells had more than two pericentrin foci, which cor-
respond to sites of ectopic microtubule nucleation, compared
to 12% of siControl cells (Figures 5C and 5D). These results
indicate that siSTARD9 cells enter mitosis with a normal number
of centrosomes and also suggest that multipolar spindles do
not arise from centriole splitting or centriole fragmentation, but
instead from fragmentation and dissociation of the PCM from
centrosomes.
Our analysis of STARD9 centered on HeLa (cervical adenocar-
cinoma) cells, but we sought to assess the importance of
STARD9 for cell division in other types of cancers. Thus, we
analyzed the consequences of depleting STARD9 in a panel of
cancer cell lines. Similar to the defects observed in HeLa cells,
HCT116 (colorectal carcinoma), H460 (non-small cell lungs ± taxol. x axis indicates oligonucleotides and y axis indicates normalized AI.
ormalized MI (over control oligonucleotides) (y axis) versus normalized AI (over
e depletions with increased MI and AI. Xs represents STARD9 RNAi.
al Procedures and Table S3.
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microtubules determined by analyzing the supernatant and pellet fractions by SDS-PAGE and Coomassie blue staining. Asterisks indicate protein bands of
interest.
(B) The ATPase activity of kinesin heavy chain (KHC), GST-Skp1, GST-tagged WT or T110N was assessed by an ATPase end point assay. Activity is in
moles/minute/mg. Error bars indicate ± SD.
(C) HeLa cells were transfected with eGFP, or eGFP-tagged WT, T110N or R223A for 24 hr. Cells were fixed and costained for a-tubulin, DNA, and eGFP (The
scale bar represents 5 mm).
(D) Recombinant GST-Skp1 or GST-WT were immobilized on a bead matrix and incubated with centrosome preparations. Samples from pelleted beads and
supernatants were resolved by SDS-PAGE and immunoblotted for a-tubulin, g-tubulin, pericentrin, and MCAK. (A-D) See also Extended Experimental
Procedures.carcinoma), and M-395 (melanoma) cells showed an increase in
the number of mitotic cells with greater than 2 pericentrin foci
(Figures 5E and S4). In contrast, only a small increase in PCM
fragmentation was observed in U2OS (bone osteosarcoma)(B) STARD9motor domain alignment. The STARD9motor domain shares 49% ide
Kinesin-3 family members is highlighted in green. Sequence C-terminal to motor d
and key residues predicting plus end directionality are in red.
(C) Cell-cycle subcellular localization of STARD9. HeLa cells were costained for
prophase to late anaphase, see arrows (The scale bar represents 5 mm).
(D) Costaining of STARD9, a-tubulin, DNA, and either centrin, pericentrin, g-tubulin
in one cell (The scale bar represents 5 mm).
(E) Costaining of STARD9, a-tubulin, DNA, and centrobin (The scale bar represen
and centrobin colocalization. (A–E) See also Extended Experimental Proceduresand MCF-7 (breast adenocarcinoma) cells and no significant
change was seen in hTERT-RPE-1 (retinal pigment epithelial
cells, which have properties of more normal cells, and show
strongly reduced responses to other antimitotic agents),ntity to KIF1A and 52% identity to KIF16B. A conserved insertionwithin loop 3 of
omain, highlighted in blue, contains polarity determining amino acids residues
STARD9, a-tubulin, and DNA. STARD9 accumulates at the centrosomes from
, NuMA, TPX2, or Kinesin-5. Zoom depictsmagnified view of two centrosomes
ts 2 mm). Bottom panel is magnified view of one centrosome showing STARD9
and Figures S1, S2, and S3.
Cell 147, 1309–1323, December 9, 2011 ª2011 Elsevier Inc. 1315
A       DNA               ACA            α-Tubulin         Merge        
si
C
on
tro
l
si
S
TA
R
D
9
C    DNA     Pericentrin  α-Tubulin   γ-Tubulin     Merge        
si
C
on
tro
l
si
S
TA
R
D
9
B    DNA         Centrin   α-Tubulin  Pericentrin    Merge
si
C
on
tro
l
si
S
TA
R
D
9
D
C
el
ls
 w
ith
 >
2 
P
er
ic
en
tri
n 
fo
ci
   
   
   
   
(P
er
ce
nt
ag
e)
siSTARD9  siControl  
Int        Mito Int        Mito 
90
80
70
60
50
40
30
20
10
0 
.25
.2
.15
.1
.05
0 
80
70
60
50
40
30
20
10
0 
90
80
70
60
50
40
30
20
10
0 
80
70
60
50
40
30
20
10
0 
10
5
     0 
25
20
15
 
E
Ce
lls
 w
ith
 >
2 
Pe
ric
en
tri
n
 fo
ci 
(P
er
ce
nt
ag
e)
HeLa HCT116 H460 M395 U2OS MCF7 MCF10 RPE  Lymph  Fibro  
siSTARD9 
H
C
el
ls
 w
ith
 >
2 
P
er
ic
en
tri
n
 fo
ci
 (P
er
ce
nt
ag
e)
GF
 1  2  3  4  5  6  7  8  9 10 
      Melanoma 
1  2  3  4  5  6  7  8  9 10 
    NSCLC 
C
el
ls
 w
ith
 >
2 
P
er
ic
en
tri
n
 fo
ci
 (P
er
ce
nt
ag
e)
Control   EGFP    WT     T110N    R223A    
I
C
el
ls
 w
ith
 >
2 
P
er
ic
en
tri
n
 fo
ci
 (P
er
ce
nt
ag
e)
Control    EGFP       WT        T110N     R223A    
1  2  3 4  5 6  7 8  9 10 
siControl    siSTARD9    
siControl    siSTARD9    
S
TA
R
D
9 
ex
pr
es
si
on
 re
la
tiv
e 
to
 G
A
P
D
H
 1 2  3  4  5  6  7 8 9 10 
      Melanoma    NSCLC 
**
*
Figure 5. STARD9 Depletion Induces Fragmentation and Dissociation of the PCM from Centrosomes in Multiple Cancer Types
(A–C) Control or STARD9 siRNA treated HeLa cells were fixed and costained for a-tubulin, DNA, and ACA (centromere marker) (A), centrin and pericentrin (B), and
pericentrin and g-tubulin (C). Scale bars represent 5 mm.
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MCF-10a (normal breast cells), lymphoblasts, and fibroblasts
(Figures 5E and S4). These results indicate that various cancer
cells are sensitive to STARD9 depletion, but not normal cells.
However, cancer subtypes tend to have varied genetic back-
grounds, checkpoint competencies, and sensitivities to drug
treatments. Therefore, we analyzed the response to STARD9
depletion in two panels of cancer cell lines, one containing 10
melanoma cell lines and the other 10 non-small cell lung carci-
noma (NSCLC) cell lines. Surprisingly, only three out of ten mela-
noma and three out of ten NSCLC cell lines displayed PCM frag-
mentation above 55% (Figure 5F). Thus, although many types of
cancer cells are sensitive to STARD9 depletion, there is a need to
identify the specific subtypes.
Deregulating the levels of microtubule-associated proteins
can contribute to tumor formation, for example, TOGp, NuMA,
and TPX2, which nucleate, crosslink, and stabilize microtubules
in mitosis are overexpressed in cancer and correlate with a high
incidence of chromosomal instability (Carter et al., 2006). Addi-
tionally, RASSF1A and MTUS1, which control mitotic progres-
sion, are underexpressed in specific cancers and act as tumor
suppressors (Rodrigues-Ferreira et al., 2009; Song et al.,
2004). Thus, we asked if proteins within the MMCP set (including
STARD9) were deregulated in cancer by analyzing the differential
gene expression levels of the MMCP set across 27 cancer
tissues versus normal samples from the same tissue (Figure S5
and Table S5). Consistent with previous studies, the spindle
checkpoint regulators Mad2L1, Bub1, and Aurora kinase B
(AurKB) clustered within a large group showing overexpression
across multiple cancer types. This set included genes involved
in centrosome (AurKA and Plk4) and spindle pole (Astrin) homeo-
stasis, suggesting that spindle poles show altered regulation in
cancer. Interestingly, STARD9 clustered with a large group
downregulated across multiple cancer types that included the
centriolar and ciliary protein Alms1 (Figure S5 and Table S5).
Consistently, qRT-PCR analysis showed that STARD9 was ex-
pressed at low levels in most cancers (Figure 5G). However,
we found no simple correlation between the basal STARD9
expression levels and the extent of PCM fragmentation induced
by STARD9 depletion.
Overexpression of the STARD9 Motor Domain Partially
Rescues PCM Fragmentation in STARD9-Depleted Cells
Possibly due to its large size, our attempts to express full length
STARD9 were unsuccessful. As the STARD9 motor domain has
microtubule binding and ATPase activities required for its local-
ization to centrosomes, we asked if expression of the motor
domain rescued the PCM fragmentation phenotype observed(D) Quantitation of the percentage of interphase (Int) and mitotic (Mito) cells with
(E) HeLa, HCT116, H460, M395, U2OS, MCF7, MCF10a, hTERT-RPE-1, lymphob
were fixed and costained for DNA, a-tubulin and pericentrin and the percentage
(F) The same analysis in (E) was carried out with panels of melanoma and non-s
(G) STARD9 mRNA expression levels relative to GAPDH in melanoma and NSCL
(H) Overexpression of STARD9-MD partially rescues PCM fragmentation. Cells
resistant eGFP-tagged STARD9motor domainWT, T110N, or R223A. Data repres
**p < 0.005.
(I) Overexpression of the STARD9 motor domain leads to a dominant negative p
expressed for 48 hr in HeLa cells and the percentage of cells with greater than two
(A–E) See also Extended Experimental Procedures, Figures S3, S4, S5, and Tabin STARD9-depleted cells. HeLa cells were cotransfected
with siSTARD9 and siRNA resistant eGFP-tagged MD-WT,
MD-T110N, and MD-R223A for 48 hr and the extent of PCM
fragmentation was determined. Overexpression of MD-WT, but
not MD-T110N or MD-R223A led to a modest but significant
rescue (10%, p value .001; Figure 5H), indicating that the
STARD9 motor domain not only localizes STARD9 to centrioles,
but also functions tomaintain PCM cohesion. Interestingly, over-
expression of MD-WT in control HeLa cells led to a modest in-
crease (9%, p value .0491) in PCM fragmentation and mitotic
spindle defects, indicating a dominant negative effect (Figure 5I).
STARD9 Is Not Required for Recruitment of Spindle Pole
Focusing Activities
Kinesins are often involved in the transport of cargo alongmicro-
tubules, therefore it was possible that STARD9s role in PCM
cohesion involved the transport of factors required for centro-
some homeostasis. Thus, we analyzed whether depletion of
STARD9 had an effect on the localization of proteins involved
in centrosome maturation (NEK2, AurKA, and Plk1), centrosome
separation (Kinesin-5), microtubule nucleation (TPX2) and spin-
dle organization (NuMA) by immunofluorescence microscopy.
NEK2, AurKA, Plk1, Kinesin-5, NuMA, and TPX2 were each
localized to spindle poles and ectopic microtubule nucleating
sites (fragmented PCM) that formed multipolar spindles in
siSTARD9 cells (Figures 6A–6C and S6A–S6C). These results
indicate that STARD9 does not recruit spindle pole focusing
activities and motors necessary for spindle bipolarity.
Depletion of STARD9 Arrests Cells in Mitosis
with an Active SAC
Depletion of STARD9 led to defects in chromosome congression
and arrested cells in early mitosis, indicative of an activated spin-
dle assembly checkpoint (SAC), which monitors microtubule-
kinetochore attachment and inter-kinetochore tension. When
active, SAC proteins like BubR1 and Bub1 reside at the kineto-
chore region and disperse upon proper microtubule-kinetochore
attachment (Musacchio and Salmon, 2007). Consistently,
siControl cells aligned their chromosomes at the metaphase
plate with minimal BubR1 and Bub1 staining (Figures 6D and
S6D). Conversely, siSTARD9 cells arrested in prometaphase
with BubR1 and Bub1 prominently localized to kinetochores
(Figures 6D and S6D). The chromosomal passenger complex
(CPC, composed of AurKB, INCENP, Survivin, and Borealin)
is a SAC complex required to arrest cells in response to lack of
inter-kinetochore tension (Ruchaud et al., 2007). At the onset
of anaphase, in siControl cells, the CPC was dynamicallygreater than two pericentrin foci.
last, and fibroblast cells were treated with siControl or siSTARD9 for 48 hr. Cells
of mitotic cells with greater than two pericentrin foci was quantified.
mall cell lung carcinoma cell lines (NSCLC).
C cell lines.
were cotransfected with siSTARD9 and vectors expressing eGFP, or siRNA
ent the average ±SD of 3 independent experiments, 100 cells counted for each.
henotype. EGFP-tagged STARD9 motor domain WT, T110N, or R223A were
pericentrin foci was quantified as in H *p < 0.05. (D–I) Error bars indicate ± SD.
les S4 and S5.
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Figure 6. STARD9 Is Not Required for Recruitment of Spindle Pole Focusing Activities and Its Depletion Activates the SAC
(A–E) Control or STARD9 siRNA treated HeLa cells were fixed and costained for STARD9, a-tubulin, DNA, and NEK2 (A), NuMA (B), Kinesin-5 (C), BUBR1 (D), and
AurKB (E). The scale bar represents 2 mm. (A–E) See also Extended Experimental Procedures and Figure S6.delocalized from the kinetochores and transitioned to the central
spindle (Figure 6E). In contrast, in siSTARD9 cells, AurKB and
INCENP remained at the kinetochore region and never redistrib-
uted to the central spindle (Figures 6E and S6E). These results
indicate that STARD9-depleted cells lack proper microtubule-
kinetochore attachments and/or inter-kinetochore tension,
which activates the SAC and arrests cells in early mitosis.
Chemical Inhibition of Cdk1, Plk1, or Kinesin-5 Function
Prevents PCMFragmentation in STARD9-DepletedCells
To define the timing and order of events leading to PCM frag-
mentation and mitotic arrest in siSTARD9 cells, we combined
siSTARD9 treatment with inhibition of mitotic regulators. Syn-
chronized siControl and siSTARD9 cells were treated with small
molecule inhibitors of Plk1 (centrosome maturation), Kinesin-5
(centrosome separation), Cdk1 (G2/M transition), and microtu-
bule dynamics (taxol and nocodazole) prior to mitotic entry.
Two hours postmitotic entry, cells were fixed and costained for
DNA, a-tubulin, pericentrin or centrin, and STARD9. Inhibition
of Plk1 with the ATP-competitive inhibitor compound 1 (Lansing
et al., 2007) arrested siControl and siSTARD9 cells with monop-
olar spindles and a focused PCM around the two centriole pairs
(Figure S7A, top panels). Similarly, inhibition of Kinesin-5 with
monastrol (Kapoor et al., 2000) arrested siControl and siSTARD9
cells with monopolar spindles and a matured PCM around the
two centriole pairs (Figure S7B, top panels). Thus, both treat-
ments blocked siSTARD9 cells from transitioning to PCM frag-
mentation, indicating that STARD9 functions to maintain PCM
cohesion downstream of centrosome maturation and separa-1318 Cell 147, 1309–1323, December 9, 2011 ª2011 Elsevier Inc.tion. Consistent with this possibility, inhibition of Cdk1 with
RO-3306 (Vassilev et al., 2006) arrested cells at the G2/M transi-
tion and prevented PCM fragmentation in siSTARD9 cells (Fig-
ure S7C, top panels) (Vassilev et al., 2006). Additionally, STARD9
did not localize to daughter centrioles in G2/Marrested cells (Fig-
ure S7C, lower panel), confirming our previous results showing
STARD9 localization to daughter centrioles only from prophase
to late anaphase (Figure 3C).
In early mitosis, microtubule-dependent forces are applied to
the centrosome by proteins that organize and form the bipolar
spindle (Abal et al., 2005). When PCM cohesion is compro-
mised, these forces fragment the PCM (Oshimori et al., 2006).
Thus, it was possible that microtubule-dependent forces played
a role in the PCM fragmentation observed in siSTARD9
cells. Under normal conditions 80% of siSTARD9 cells exhibit
PCM fragmentation compared to 10% of siControl cells (Fig-
ure 5D). However, depolymerization of microtubules with noco-
dazole treatment drastically reduced PCM fragmentation in
siSTARD9 cells to undetectable levels (Figure S7D, top panels).
Interestingly, stabilization of microtubules in siSTARD9 cells
with taxol treatment (interferes with microtubule-dependent
forces) also modestly reduced PCM fragmentation (to 51%;
Figure S7E, top panels). These results indicate that microtu-
bule-dependent forces drive PCM fragmentation in siSTARD9
cells. In addition, STARD9 was weakly localized to centrioles
in taxol treated cells and absent in nocodazole treated cells
(Figure S7D lower panels and S7E, right panels), indicating
that the localization of STARD9 to the centrioles requires
microtubules.
STARD9 Depletion Induces Mitotic Apoptosis
Since siSTARD9 cells exhibited elevated levels of mitotic arrest,
SAC activation, and apoptosis, we hypothesized that they were
apoptosing in mitosis. To test this, we imaged siControl and siS-
TARD9 cells by time-lapse microscopy using a HeLa cell line ex-
pressing eGFP-histone 2B to mark chromosomes. In control
cultures, 90% of cells transitioned through mitosis with normal
kinetics (80 min) and 10% had defects in chromosome con-
gression. In contrast, 75% of siSTARD9 cells had defects in
chromosome congression and arrested in mitosis for an average
of 3.5 hr, at which time their chromatin became fragmented and
highly condensed, indicative of apoptosis (Figures 7A and 7B,
Movies S1 and S2).
To substantiate our in vivo findings, we tested siSTARD9 cells
for biochemical hallmarks of apoptosis, namely DNA fragmenta-
tion, apoptosis, and a decrease in cell viability. Synchronized si-
Control and siSTARD9 cells were fixed 5 hr postmitotic entry and
analyzed by the DeadEnd fluorometric TUNEL assay (Promega)
for DNA fragmentation (see Supplemental Information). In this
assay DNA breaks are labeled with fluorescein-12-dUTP and
can be visualized and quantified by fluorescence microscopy.
In contrast to siControl cells, siSTARD9 cells had a marked
increase in TUNEL-positive cells (Figure 7C). Apoptosis relies
on the activation of initiator (caspase 9) and effector (caspase
3/7) caspases (Chowdhury et al., 2008). Thus, we analyzed
whether these caspases were activated in siSTARD9 cells.
Seventy-two hours posttransfection, asynchronous siControl,
siPlk1, or siSTARD9 cells were fixed and the AI was measured
as described in our apoptotic screen. Depletion of STARD9 or
Plk1 led to an increased AI, confirming our screen results and
published data (Petronczki et al., 2008) (Figure 7D). We then
measured the cell viability of siControl and siSTARD9 cells using
the CellTiter-Glo assay that measures total ATP levels (indicative
of metabolically active cells) at 24, 48, 72, 96, and 120 hr post-
siRNA transfection. As expected, the viability of siSTARD9 cells
decreased over time compared to siControl cells (Figure 7E).
These results indicate that STARD9 depletion leads to mitotic
arrest, activation of apoptosis and mitotic cell death.
STARD9 Depletion Synergizes with Taxol Treatment
Although paclitaxel (Taxol) remains one of the most widely used
anticancer agents, its efficacy is limited by neutropenia and
neurotoxicities. If a combination treatment were to shift the
dose-efficacy curve, it might be possible to improve the thera-
peutic index and efficacy of taxol. Thus, we asked if depletion
of STARD9 could synergize with taxol to induce apoptosis. si-
Control and siSTARD9 cells were treated with increasing
concentrations of taxol 48 hr posttransfection and their AI was
measured 72 hr posttransfection. Indeed, depletion of STARD9
increased the apoptotic response with increasing concentra-
tions of taxol, with an IC50 of 1.15 mM for siSTARD9 and IC50 of
3.28 mM for siControl (Figure 7F). siSTARD9 treatment also
increased the peak AI by 1.73, consistent with a higher
percentage of cells undergoing apoptosis at this time point.
These results indicate that depletion of STARD9 synergizes
with taxol treatment.
The SAC including Mad2 and BUBR1 plays a critical role in the
induction of mitotic apoptosis. Thus, we asked if siSTARD9-induced apoptosis was dependent on the SAC by depleting
BUBR1 and assessing its effect on the siSTARD9-taxol combi-
nation treatment. In comparison to siSTARD9, codepletion of
STARD9 and BUBR1 led to a marked decrease in AI (Figure 7F),
indicating that the SAC plays a critical role in the induction of
mitotic apoptosis in siSTARD9 cells. Furthermore, addition of
ZVAD, caspase inhibitor, led to a complete inhibition of siS-
TARD9-induced apoptosis (Figure 7F).
DISCUSSION
The importance of mitotic spindle assembly to cell division and
cancer biology has fueled intensive study of this structure. Our
interest in identifying targets for cancer therapeutics prompted
us to conduct a focused screen for regulators of mitosis. We
report the identification of 592 mitotic microtubule copurifying
proteins by mass spectrometry and analysis of their contribution
to mitosis by functional RNAi screens for mitotic arrest, check-
point bypass, and induction of apoptosis. Interestingly, we iden-
tified a kinesin, STARD9, with a critical role in cancer cell division.
Several insights have emerged from our studies. First, we have
uncovered a previously undescribedmitotic kinesin whose local-
ization and function is unique and significantly different from
other kinesins. Second, based on STARD9s function and enzy-
matic activity, it appears to be a potential cancer target. Third,
the triggers that induce mitotic apoptosis are poorly-defined
and our study indicates that compromising the integrity of the
PCM may have a role in inducing apoptosis. Finally, our study
highlights the utility of performing focused siRNA screens to
understand cellular processes, as many of the genes we have
identified as regulating mitosis and apoptosis were not identified
in previous genome-wide screens for mitotic regulators (Kittler
et al., 2007).
Role of STARD9 in Mitosis
STARD9-depletion shares many phenotypic similarities to
depletion of Kizuna, a centrosomal protein critical for centro-
some integrity and spindle bipolarity, which forms a bond that
tethers the expanded PCM to the centriole (Oshimori et al.,
2006). Kizuna is also a Plk1 substrate and functions downstream
of Plk1-mediated PCM organization in early mitosis (Oshimori
et al., 2006). Similar to Kizuna, we hypothesize that STARD9
stabilizes the PCM under microtubule-mediated tension during
bipolar spindle assembly. However, the localization of STARD9
to centrioles indicates that unlike Kizuna, which forms a general
PCM bond, STARD9 may form a link between the daughter
centriole and the PCM. Interestingly, both Kizuna and STARD9
are conserved among vertebrates, but not invertebrates or other
lower eukaryotes (Figure S2). It is intriguing to consider whether
higher eukaryotes may have more sophisticated centrosome
compositions that allow them to accommodate the microtu-
bule-mediated tension that occurs during the formation of
a bipolar spindle.
Identification of STARD9 interacting proteins will be critical to
understanding its role in mitosis. A recent genome-wide yeast
two-hybrid analysis identified an interaction between STARD9
and CDK5RAP2 (the human homolog of D. melanogaster Cen-
trosomin) (Stelzl et al., 2005). CDK5RAP2 localizes toCell 147, 1309–1323, December 9, 2011 ª2011 Elsevier Inc. 1319
Figure 7. STARD9 Depletion Induces Mitotic Apoptosis and Synergizes with Taxol
(A and B) Time-lapse microscopy of HeLa-GFP-H2B cells treated with control or STARD9 siRNA, frames are at 5 min intervals (see Movies S1 and S2).
(B) Twenty siControl or siSTARD9 cells were visualized by time-lapse microscopy and chromosome congression and mitotic outcome were quantified.
(C) Visualization of DNA fragmentation in siControl or siSTARD9 HeLa cells with the DeadEnd Fluorometric TUNEL assay. Cells were fixed and imaged 5 hr
postmitotic entry.
(D) Caspase 3/7 and 9 activity was determined for siControl, siSTARD9, or siPlk1 HeLa cells. The apoptotic index (AI, Caspase-Glo/CellTiter-Glo) was quantified
and plotted on a log scale as arbitrary units.
(E) STARD9 depletion decreases cell viability. Total ATP levels (CellTiter-Glo assay) were quantified in siControl and siSTARD9 cells at indicated time points
post-siRNA transfection.
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centrosomes during mitosis and has been implicated in centriole
engagement, PCM cohesion, and microtubule nucleation (Bar-
rera et al., 2010; Choi et al., 2010). However, a detailed analysis
will be necessary to determine if the STARD9-CDK5RAP2 inter-
action is important for PCM cohesion. Future efforts to define
the mechanism of STARD9s’ function will benefit from biochem-
ical purifications and mass spectrometry analyses aimed at
identifying STARD9 interacting proteins, which may cooperate
with STARD9 or regulate STARD9 activity.
The localization of STARD9 to daughter centrioles is unique, as
centrobin is the only protein known to predominantly localize to
daughter centrioles (Zou et al., 2005). However, unlike centrobin,
STARD9 centriolar localization is cell-cycle-regulated, appearing
only at the onset of prophase and disappearing by cytokinesis
(Figure 3C). Treatment with nocodazole abolishes this localiza-
tion indicating that it is microtubule-dependent (Figure S7D).
Interestingly, the STARD9 motor domain displays microtubule
binding and ATPase activities, both of which are required for
its centriolar localization (Figure 4C).
STARD9 Depletion and Apoptosis
The triggers that activate the apoptotic pathway in mitosis are
poorly understood. Interestingly, Plk1 and Kinesin-5 inhibitors
tend to arrest the cells in mitosis for prolonged lengths of time
(up to 18 hr) before the induction of apoptosis (Petronczki
et al., 2008; Shi et al., 2008). However, the induction of apoptosis
observed in STARD9-depleted cells appears to show rapid
kinetics, implying that siSTARD9 prometaphase arrest differs
from that observed in Plk1 and Kinesin-5 inhibited cells. It is
tempting to consider that PCM fragmentation, defective micro-
tubule dynamics, or DNA tearing observed in STARD9-depleted
cells (Figures 5 and 7) are important apoptotic triggers and
should be explored further.
STARD9 as a Cancer Target
Several of our findings indicate that inhibition of STARD9s enzy-
matic activity may be a viable approach to inhibiting cancer cell
division. First, the PCM fragmentation and spindle assembly
defects caused by STARD9-depletion appear to be conserved
among multiple cancer cell lines and not in normal cell lines (Fig-
ure 5E and S4). Second, siSTARD9 cells apoptose duringmitosis
and with faster kinetics than other antimitotic treatments like
Kinesin-5 or Plk1 inhibition. Third, the STARD9 microtubule
binding and ATPase activities are critical to its localization to
centrioles and function in PCM cohesion (Figures 4C and 5H).
Fourth, depletion of STARD9 synergizes with taxol treatment
(Figure 7F), opening the possibility for combined therapies.
Many details of STARD9 function will need to be explored to fully
assess its potential as a cancer target, including a structure-
function analysis. In addition, as the basal expression levels of
STARD9 do not correlate with the level of STARD9-depletion(F) Depletion of STARD9 synergizes with taxol treatment and is dependent on the
STARD9 + BUBR1 siRNAwere incubated with increasing concentrations (0–10 mm
molecule ZVAD was added to STARD9 siRNA-treated cells.
(G) Model: STARD9 localizes to daughter centrioles in prophase and stabilizes th
(B, E, and F) Error bars indicate ± SD.
(A–G) See also see Supplemental Experimental Procedures, Figure S7, and Movsensitivity, future studies should be aimed at identifying the
variables that lend specific types of cancers responsive to
STARD9 inhibition. Finally, it is possible that the low STARD9
levels observed in many cancers could be a contributing factor
to cancer progression and should be analyzed further.
EXPERIMENTAL PROCEDURES
Cell Culture
HeLa cells were grown in F12:DMEM 50:50 medium (GIBCO) with 10% FBS,
2 mM L-glutamine and antibiotics, in 5% CO2 at 37
C. To obtain synchronized
HeLa cells in mitosis, cells were treated with 300 nM nocodazole (Sigma-
Aldrich) for 18 hr. To synchronize HeLa cells in G1/S, cells were treated with
2 mM thymidine (Sigma-Aldrich) for 18 hr. For in vivo small molecule inhibition,
cells were incubated with 100 mM Monastrol (Sigma-Aldrich) (Kinesin-5
inhibition), 200 nM compound 1 (GlaxoSmithKline) (Plk1 inhibition), 10 mM
R0-3306 (EMDChemicals) (Cdk1 inhibition), 5 mM taxol, or 300 nM nocodazole
6 hr postrelease, fixed, and stained 4 hr post-small-molecule addition. For
gene knockdowns, cells were transfected with indicated Dharmacon ON-
TARGETplus siRNA at 50 nM using Lipofectamine RNAiMAX (Invitrogen)
for 48 hr.
Microtubule Aster Copurifying Proteins
Mitotic aster microtubule copelleting assays were performed essentially as
described in (Mack and Compton, 2001). Sixteen 15 cm plates of nocodazole
(300 nM for 18 hr) arrested mitotic HeLa cells were harvested bymitotic shake-
off, washed in PBS plus 20 mg/ml cytochalasin B (Sigma-Aldrich) twice,
washed with KHMD (78 mM KCL, 50 mM HEPES [pH 7.0], 4 mM MgCl2,
2 mM EGTA, 1 mM DTT, 20 mg/ml cytochalasin B) once and resuspended in
KHMDL (KHMD plus protease inhibitors leupeptin-pepstatin-chymostatin
1 mg/ml). Cells were dounce homogenized and extracts were cleared by ultra-
centrifugation at 38,000 RPM for 15 min. All steps were carried out at 4C
unless otherwise noted. Cleared lysates were supplemented with 5 mg/ml
latrunculin B (Sigma-Aldrich). Microtubule polymerization reactions were
carried out in the presence of control vehicle DMSO or 10 mM taxol (Sigma-
Aldrich) at 33C for 30 min. Polymerization reactions were layered onto a
50%W/V sucrose/KHM cushion supplemented with 10 mM taxol for reactions
with taxol-stabilized microtubules. Layered reactions were centrifuged for 2 hr
at 39,000 RPM in a TLS-55 (Beckman) swinging bucket ultracentrifuge rotor.
The microtubule copelleting fraction was washed three times with KHM buffer
and processed for LC-MS/MS analysis (see Extended Experimental
Procedures).
RNAi Screen Conditions
Dharmacon ON-TARGETplus siRNA smart pools and individual oligos target-
ing the MMCP gene set were arrayed on 96-well plates. For transfection,
Oligofectamine (Invitrogen) in OPTI-MEM (Invitrogen) was added to each
well of a 96-well plate (poly-D-Lysine coated, Beckton Dickinson Labware)
containing the prespotted siRNA library. The mixture was incubated for
40 min and HeLa cells, 10,000 cells/well, were plated onto the siRNA mixture
using a multidrop combi (Thermo Scientific) to ensure even distribution. Cells
were incubated at 37C for indicated times. For + taxol screens, taxol (100 nM
final concentration) was added to each well 24 hr posttransfection using
a RapidPlate liquid handler (Caliper Life Sciences). For mitotic arrest screens,
48 hr posttransfection cells were fixed by paraformaldehyde (4% final concen-
tration) perfusion for 15min at room temperature. Following fixation, cells were
permeabilized with .2% Triton X-100/PBS for 5 min at room temperature.
Plates were washed with PBS one time and stained for phosphohistone H3spindle assembly checkpoint. Cells treated with control, STARD9, BUBR1, or
) of taxol and the apoptotic index was quantified as in D. Additionally, the small
e PCM during bipolar spindle assembly.
ies S1 and S2.
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and DNA (1:50 Alexa 488 phosphohistone H3 (Ser10) (Cell Signaling) and
1 mg/ml Hoechst 33342 in 5% fish gelatin (Invitrogen) for 1 hr. After staining
plates were washed two times with .1% Triton X-100/TBS using a BioTek
microplate washer ELx405 (BioTek Instruments). Screen plates were imaged
on a Cellomics ArrayScanVTI HCS Reader (Cellomics). The ArrayScan/
vHCS:Scan software was used for image acquisition using the following
parameters: objective: 103 .5 NA, bio application algorithm: Spot Detector,
number of channels: two Hoechst and FITC, focus channel: Hoechst, scan
limits: 1,000 objects (nuclei), with background correction and object segmen-
tation on. Data was analyzed using ArrayScan/vHCS:View software and
exported to Excel spreadsheets. For apoptotic screens, 72 hr posttransfection
cells were fixed and subjected to the Caspase-Glo assay (Promega) or the
CellTiter-Glo assay (Promega) and the apoptotic index (AI, caspase activity
per cell/ATP levels as described in (Peterson et al., 2010) was measured
using a luminometer. For statistical analysis, see Extended Experimental
Procedures.
Motor Domain Analysis
For STARD9 motor domain expression (modified from (Moyer et al., 1996),
microtubule-binding assays (as described in (Goode and Feinstein, 1994),
centrosome binding assays (as described in (Mitchison and Kirschner,
1986), ATPase assays (as described in (Funk et al., 2004), localization studies,
and rescue experiments, the first 387 amino acids of STARD9 (WT, T110N, and
R223A) were fused to the C terminus of either GST (pGEX-6P vector) or eGFP
(pGLAP1 vector, (Torres et al., 2009). For localization, overexpression, and
rescue experiments, eGFP, or eGFP-tagged STARD9-MD-WT, T110N, or
R223A were transfected in to HeLa cells for the indicated times. Cells were
fixed and stained for DNA, a-tubulin, eGFP, and pericentrin. For centrosome
binding experiments, 100 mg of GST-STARD9-MD or GST-Skp1, were pre-
bound to glutathione agarose beads, and incubated with 500 mg of mitotic
centrosome preps, after 1 hr beads were pelleted, washed three times with
110 mM NaCl, 5mM ATP, 80mM PIPES (pH 6.9), 5mM MgCl2, 1mM EGTA,
and samples from the first supernatant and the pellet fraction were resolved
by SDS-PAGE and analyzed by immunoblot with indicated antibodies.
Immunofluorescence
Immunofluorescence was carried out essentially as described in (Torres et al.,
2010).
HeLa cells were transfected with control or indicated siRNA (ON-
TARGETplus siRNA, Dharmacon) for 48 hr, fixed with 4% paraformaldehyde,
permeabilized with 0.2% Triton X-100/PBS, and costained with 0.5 mg/ml
Hoechst 33342 and indicated antibodies. Images were captured with a Zeiss
Axio Imager.Z1 microscope and processed using SlideBook 4.2 (Intelligent
Imaging).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
tables, two movies, and seven figures and can be found with this article online
at doi:10.1016/j.cell.2011.11.020.
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